Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Copaxone, a glatiramer acetate injection has demonstrated significant reduction in loss of brain volume in patients with relapsing-remitting multiple sclerosis (RRMS) as compared to other disease modifying therapies (DMTs).
Subscribe to our email newsletter
The trial comprised 121 patients who were treated with Copaxone, 101 were treated with Betaseron or Rebif (high-dose interferon) and 53 were treated with Avonex (low-dose interferon).
The five-year study showed that Copaxone had better effect than both low and high dose interferons, in reducing loss of brain volume.
The study which was supported by Wayne State University Neuroscience Program was published in the Journal of the Neurological Sciences.